Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Shurui Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6814-7074; OpenAlex author ID A5050986874. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 4 papers

Papers 8

  1. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. Co-author DOI 10.1002/jev2.12484↗
  2. Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.216784↗
  3. Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216840↗
  4. Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancer. Co-author DOI 10.1016/j.mcp.2023.101948↗
  5. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Co-author DOI 10.1016/j.phrs.2022.106555↗
  6. Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients. First author DOI 10.1186/s13014-023-02273-w↗
  7. A LETM2-Regulated PI3K-Akt Signaling Axis Reveals a Prognostic and Therapeutic Target in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194722↗
  8. GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network. Co-author DOI 10.7150/jca.72161↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaihong Huang · 7 shared papers, 2022–2024 · strength 1.20
  2. Jinmao Zou · 6 shared papers, 2022–2024 · strength 1.06
  3. Yaqing Li · 5 shared papers, 2022–2024 · strength 0.87
  4. Shaojie Chen · 5 shared papers, 2022–2024 · strength 0.82
  5. Guoda Lian · 5 shared papers, 2022–2024 · strength 0.80
  6. Yuzhou Huang · 4 shared papers, 2022–2024 · strength 0.74
  7. Ziyi Zhong · 4 shared papers, 2022–2024 · strength 0.73
  8. Kege Yang · 4 shared papers, 2022–2024 · strength 0.73
  9. Yue Zhao · 3 shared papers, 2024 · strength 0.59
  10. Yunlong Li · 3 shared papers, 2022–2024 · strength 0.56
  11. Hanming Yao · 3 shared papers, 2023–2024 · strength 0.54
  12. Jiajia Li · 2 shared papers, 2023–2024 · strength 0.35
  13. Fengjiao Li · 2 shared papers, 2022–2023 · strength 0.29
  14. Hui Deng · 1 shared paper, 2024 · strength 0.23
  15. Jianchang Shu · 1 shared paper, 2024 · strength 0.23
  16. Shaojie Chen · 1 shared paper, 2024 · strength 0.20
  17. Jiajia Li · 1 shared paper, 2024 · strength 0.20
  18. Yanji Luo · 1 shared paper, 2023 · strength 0.18
  19. Ming Gao · 1 shared paper, 2023 · strength 0.18
  20. Shangxiang Chen · 1 shared paper, 2023 · strength 0.16
  21. Yue Zhao · 1 shared paper, 2023 · strength 0.16
  22. Shangxiang Chen · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.